Corporate strategies for managing bioethical issues

Drug Discovery Today

Volumn 8, Issue 9, 2003, Pages 386-388

  Arakelian, Christine ^a  

^a Large Scale Biology Corporation   (United States)

Author keywords

Best Practices; Bioethicists; Bioethics; Corporations; Drug Discovery; Pharmaceutical Science; Public Relations; Risk Management; Strategy

Indexed keywords

COMMERCIAL PHENOMENA; COST BENEFIT ANALYSIS; CULTURAL FACTOR; ETHICS; HUMAN; INDUSTRY; MANAGEMENT; MARKETING; MORALITY; PERCEPTION; POLITICS; SHORT SURVEY; SOCIAL CARE; SOCIAL STATUS;

BIOETHICAL ISSUES; BIOTECHNOLOGY; DRUG INDUSTRY; ETHICS, BUSINESS; RISK MANAGEMENT;

EID: 0037404064     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(03)02671-0     Document Type: Short Survey

References (5)

1. Kunreuther H., Slovic P. Coping with stigma, challenges and opportunities. Flynn J., et al. Risk, Media and Stigma. 2001;335 Earthscan Publications, London, UK.
2. Kasperson R., et al. Stigma and the social amplification of risk: toward a framework of analysis. Flynn J., et al. Risk, Media and Stigma. 2001;16-19 Earthscan Publications, London, UK.
3. Kunreuther H., Slovic P. Coping with stigma, challenges and opportunities. Flynn J., et al. Risk, Media and Stigma. 2001;336 Earthscan Publications, London, UK.
4. Sagar A., et al. The tragedy of the commoners: biotechnology and its publics. Nat. Biotechnol. 18:2000;2-4.
5. Singer P.A., Daar A.S. Avoiding frankendrugs. Nat. Biotechnol. 18:2000;1225.